Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on February 23, 2009

Circulation. 2009
Published online before print February 23, 2009, doi: 10.1161/CIRCULATIONAHA.108.774752
A more recent version of this article appeared on March 10, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Correction
Right arrow Data Supplement
Right arrow Correction (v119,pe533)
Right arrow All Versions of this Article:
119/9/1231    most recent
CIRCULATIONAHA.108.774752v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chakir, K.
Right arrow Articles by Kass, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chakir, K.
Right arrow Articles by Kass, D. A.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*Protein
*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Failure
*Pacemakers and Implantable Defibrillators
Related Collections
Right arrow Contractile function
Right arrow Congestive
Right arrow Pacemaker
Right arrow Animal models of human disease
Right arrow Heart failure - basic studies
Right arrow Receptor pharmacology
Right arrowRelated Article

Submitted on February 21, 2008
Accepted on November 24, 2008

Mechanisms of Enhanced {beta}-Adrenergic Reserve From Cardiac Resynchronization Therapy

Khalid Chakir PhD, Samantapudi K. Daya MD, Takeshi Aiba MD, PhD, Richard S. Tunin MS, Veronica L. Dimaano MD, Theodore P. Abraham MD, Kathryn Jacques BA, Edwin W. Lai PhD, Karel Pacak MD, Wei-Zhong Zhu MD, PhD, Rui-ping Xiao PhD, Gordon F. Tomaselli MD, PhD, and David A. Kass MD*

From the Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore (K.C., S.K.D., T.A., R.S.T., V.L.D., T.P.A., K.J., G.F.T., D.A.K.); Reproductive Biology and Medicine Branch, Section on Medical Neuroendocrinology, National Institute of Child Health and Human Development, Bethesda (K.P.); and Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore (E.W.L., W.-Z.Z., R.-p.X.), Md.

* To whom correspondence should be addressed. E-mail: dkass{at}jhmi.edu.

Background—Cardiac resynchronization therapy (CRT) is the first clinical heart failure treatment that improves chamber systolic function in both the short-term and long-term yet also reduces mortality. The mechanical impact of CRT is immediate and well documented, yet its long-term influences on myocyte function and adrenergic modulation that may contribute to its sustained benefits are largely unknown.

Methods and Results—We used a canine model of dyssynchronous heart failure (DHF; left bundle ablation, atrial tachypacing for 6 weeks) and CRT (DHF for 3 weeks, biventricular tachypacing for subsequent 3 weeks), contrasting both to nonfailing controls. CRT restored contractile synchrony and improved systolic function compared with DHF. Myocyte sarcomere shortening and calcium transients were markedly depressed at rest and after isoproterenol stimulation in DHF (both anterior and lateral walls), and CRT substantially improved both. In addition, {beta}1 and {beta}2 stimulation was enhanced, coupled to increased {beta}1 receptor abundance but no change in binding affinity. CRT also augmented adenylate cyclase activity over DHF. Inhibitory G-protein (G{alpha}i) suppression of {beta}-adrenergic stimulation was greater in DHF and reversed by CRT. G{alpha}i expression itself was unaltered; however, expression of negative regulators of G{alpha}i signaling (particularly RGS3) rose uniquely with CRT over DHF and controls. CRT blunted elevated myocardial catecholamines in DHF, restoring levels toward control.

Conclusions—CRT improves rest and {beta}-adrenergic–stimulated myocyte function and calcium handling, upregulating {beta}1 receptors and adenylate cyclase activity and suppressing Gi-coupled signaling associated with novel RGS upregulation. The result is greater rest and sympathetic reserve despite reduced myocardial neurostimulation as components underlying its net benefit.


Key words: adenylate cyclase • heart failure • myocytes • pacing • receptors, adrenergic, beta • RGS proteins


Related Article:

Clinical Summaries
Circulation 2009 119: 1177-1179. [Extract] [Full Text]



This article has been cited by other articles:


Home page
Circ Cardiovasc GenetHome page
A. S. Barth, T. Aiba, V. Halperin, D. DiSilvestre, K. Chakir, C. Colantuoni, R. S. Tunin, V. L. Dimaano, W. Yu, T. P. Abraham, et al.
Cardiac Resynchronization Therapy Corrects Dyssynchrony-Induced Regional Gene Expression Changes on a Genomic Level
Circ Cardiovasc Genet, August 1, 2009; 2(4): 371 - 378.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Vanderheyden and J. Bartunek
Cardiac Resynchronization Therapy in Dyssynchronous Heart Failure: Zooming in on Cellular and Molecular Mechanisms
Circulation, March 10, 2009; 119(9): 1192 - 1194.
[Full Text] [PDF]